Skip to main content

Table 1 Summary of phase III and retrospective study of CRT for elderly patients with esophageal cancer

From: Chemoradiation in elderly esophageal cancer patients: rationale and design of a phase I/II multicenter study (OSAGE)

Authors

S

n

Age, mean, (range)

Treatment

Acute toxicities

Late toxicities

Survival

Song et al.

R

82

76

(70–87)

Paclitaxel 135 mg/m2

J1-J29

Leucopenia G4 10%

Esophageal stenosis 14,6%

mean PFS 18,2 m

   

CDDP 30 mg/m2

J1 J3 - J29 J31

Esophagitis G4 2%

radiation pneumonia 7%

2 years PFS I-II 64%

   

RTE 60 Gy

Thrombopenia

G4 1%

2 years PFS III IV 21%

Su et al.

R

96

73

(65–82)

5FU

 

radiation pneumonia 15%

1 year PFS 70,9 m

   

CDDP

  

3 years PFS 52 m

   

RTE 56–66 Gy Extensive or

conventional

 

Zhong et al.

RA

79

 

RTE 56–59.4 Gy

  

mean PFS 19,7 m

   

Docetaxel 25 mg/m2 and

CDDP 25 mg/m2 weekly

1 year 78,5 / 61,2

   

post RTCT Docetaxel

60 mg/m2 and

CDDP 75 mg/m2

  

Wang Jing et al.

R

100

76

(70–88)

CRT 50.4–66 CDDP-5FU-Docetaxel 4 courses

Leucopenia 21%

radiation pneumonia 13%

mean PFS CRT 15 m

    

Esophagitis 12%

1 year PFS CRT 58%

    

Pneumonia 10%

 

Li et al.

R

32

74

(70–90)

RT 50–60 Gy

Esophagitis G3–4: 25%

mean PFS 23 m

   

CT: Docetaxel weekly,

CDDP-5FU,

carboplatine-paclitaxel

   

paclitaxel only, doxifluridine

  

Zhonghua et al.

R

89

 

RT 60 Gy: extensive or conventional

Leucopenia G3 33%

overall 3 year survival 32,8%

   

CT paclitaxel 125 mg/m2

CDDP 20 (or oxaliplatine)

Uno et al.

R

17

79

(75–85)

RT 50–60 Gy

Leucopenia G3 2%

median survival 9 months

   

CT CDDP 5FU

  

OS 1 year 39%

Semrau et al.

R

15

74.1 (70–85)

RT 63 Gy

 

radiation pneumonia 4 pts

OS 13,9 m

   

CDDP 20 mg/m2 and 5FU

Esophageal stenosis 9 pts

mean PFS 9,5 m

Anderson et al.

R

25

77

(66–88)

RT 50.4 Gy

Leucopenia G4 16%

mean OS 35 months

   

CT 5FU Mitomycine

 

1 year OS 80%

Tougeron et al.

R

109

74.4 (70–88)

RTE 50–55 Gy

Any G3 22%

median OS 15,2 +/− 3 m

   

5FU CDDP

one toxic death from sepsis

2 year survival rates 35,5%

Tougeron et al.

R

151

mean 75 +/−4.1

CRT 50–55 Gy,

CDDP 5FU

Any G3 24.3% (mainly vomiting)

median OS 17,5 months

    

and neutropenia

2-year survival 36,6%

Xu et al.

R

20

76

(70–88)

CRT 5FU CDDP

acute pneumonia G3–4: 5%

OS 17 months

      

CRT mean PFS 14 months

Mak et al.

R

28

79.5 (75–89)

CRT 50.4 Gy

5FU CDDP

any G4 38%

Esophageal G3 17%

median survival 12.4 months

    

any G3 73.5%

no late pulmonary

    

acute neutropenia G4: 23.5%

    

one death from sepsis

 

Tumori et al.

R

57

69

CRT

  

median survival 11,2 months

Servagi et al.

RA

30

85

(79–92)

CRT 50Gy CDDP only or

Oxalipatin only

Dysphagia G4 13.3%

radiation pneumonia 10%

PFS at 1 year 40%

      

Three year OS 22%

  1. Abbreviations: S study design, R retrospective study, RA Randomized study, G grade, PFS progression-free-survival, CRT chemoradiation, n number of patients, CDDP cisplatine